MedTrace Logo

The Germinal Peptide Eye Drops in Healthy Volunteers in a Clinical Study

NCT03967548 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2021-09-17

No results posted yet for this study

Summary

The subjects of this study were healthy subjects, who were given medicine in a single dose group: 0.004%.

Conditions

  • Corneal Defect

Interventions

DRUG

Germinal peptide eye drops

Germinal peptide eye drops of 0.004%

Sponsors & Collaborators

  • Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiuli Zhao, PHD · Beijing Tongren Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-09
Primary Completion
2021-05-16
Completion
2021-06-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03967548 on ClinicalTrials.gov